Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008909 | 1.00 | SMYD3 (0.43) | SMYD3OPRK1OPRD1ATMDPP4 | |
| SCHEMBL7008363 | 0.91 | SMYD3 (0.43) | SMYD3OPRK1OPRD1DPP4HDAC8 | |
| SCHEMBL7012431 | 0.88 | OPRK1 (0.44) | SMYD3OPRK1OPRD1DPP4HDAC8 | |
| SCHEMBL7012359 | 0.81 | DPP8 (0.47) | SMYD3 | |
| SCHEMBL7012362 | 0.81 | DPP8 (0.47) | SMYD3 | |
| SCHEMBL5658459 | 0.81 | CYP3A4 (0.47) | SMYD3 | |
| SCHEMBL3279461 | 0.81 | OPRK1 (0.47) | SMYD3OPRK1OPRD1DPP4HDAC8 | |
| SCHEMBL5891540 | 0.80 | HDAC8 (0.60) | OPRK1OPRD1DPP4HDAC8 | |
| SCHEMBL7013786 | 0.79 | CALCRL (0.42) | SMYD3OPRK1OPRD1HDAC8 | |
| SCHEMBL30429936 | 0.79 | DPP4 (0.60) | SMYD3OPRK1OPRD1DPP4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1163239-B1 | MODIFIED AMINO-ACID AMIDES AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-05-28 | — | — | EP | disclosed |
| US-6313097-B1 | TREATMENT OR PROPHYLAXIS OF MIGRAINE OR CLUSTER HEADACHES, NON-INSULIN-DEPENDENT DIABETES MELLITUS, INFLAMMATION, ALLERGIC RHINITIS, ASTHMA, MORPHINE TOLERANCE, MENOPAUSAL HOT FLASHES, DISEASES CHARACTERIZED BY EXCESSIVE VASODILATATION | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-06 | — | — | US | disclosed |